BOB体育

Skip to main content

UM School of BOB体育 Research Shows Less Severe Cases of Diarrheal Illness can Still Lead to Child Deaths, Even Weeks Following Onset of the Illness

January 09, 2020 | Joanne Morrison

Myron M. Levine, MD, DTPH

Landmark GEMS Research Could Help Set Path to Reduce Child Mortality Linked to Diarrheal Illness

Diarrheal diseases are a leading cause of death for young children, accounting for nine percent of all deaths worldwide in children under five years of age, with most occurring in children under two years of age. Now, researchers at the University of Maryland School of BOB体育 (UMSOM) found that even milder cases of diarrheal diseases can lead to death in young children.

This research, the latest report from the , 鈥減rovides a strong rationale for vigorously acting to prevent or to treat all cases of diarrheal illness, regardless of severity,鈥� according to Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Diseases. Dr. Levine, who served as the overall coordinating investigator for GEMS research, led a large international consortium of investigators from North America, Europe, sub-Saharan Africa, South Asia and Australia.

鈥淥ur international team of investigators showed that for the individual child moderate-to-severe diarrheal illness posed a significantly greater risk of death than less-severe diarrhea. However, in the overall pediatric populations in which our team worked, more total deaths derive from less-severe cases of diarrhea because they are more than three times more common than moderate-to-severe cases,鈥� said Dr. Levine.

Since many of the deaths occurred more than 14 to 21 days after the children were enrolled in the study, Dr. Levine suggests that where resources and logistics make it feasible active follow-up visits and interventions for all cases of diarrhea could help reduce fatalities.

Karen Kotloff, MDGEMS, funded by the , is the largest, most comprehensive study of childhood diarrheal diseases ever conducted in developing country settings. The study, under the direction of Karen Kotloff, MD, Professor of Pediatrics at UMSOM and the Principal Investigator for Clinical and Epidemiological Research in GEMS, enrolled 22,568 children under five years of age in developing country settings including The Gambia, Kenya, Mali, Mozambique, Bangladesh, India and Pakistan. Dr. Kotloff, previously reported that children who were stunted at baseline (a sign of malnutrition) were significantly more likely to die during the two to three months following their GEMS diarrheal illness. The additional adverse nutritional consequences (stunting) that followed GEMS diarrhea cases may further increase the risk of severe or fatal outcomes.

Dr. Kotloff noted that the Lancet Global Health report showed that the risk of death from diarrheal illness was greater among young children in the four GEMS sites in sub-Saharan Africa than in the three sites in South Asia. She further noted that at the one site in Asia (Pakistan) where the risk of death following diarrhea was higher than at the other two Asian sites (India and Bangladesh), the Pakistani children were significantly more malnourished at baseline, providing further proof that malnutrition unfavorably affects the outcome of diarrheal illness.

Leading Cause of Death in Young Children

Globally, diarrheal diseases are the second leading cause of death among children under five years after the newborn period, despite the existence of effective treatments such as oral rehydration solutions (ORS) and zinc supplements and preventions such as rotavirus vaccines. This amounts to more than half a million deaths each year globally. Although many different bacteria, viruses and protozoal pathogens cause diarrheal disease, this recent report from GEMS shows that a relatively small number of pathogens were associated with a significantly increased risk of death, including three different categories of diarrhea-causing Escherichia coli, Shigella, Aeromonas, and two protozoans (Cryptosporidium and Entameba histolytica). Among these pathogens, Shigella can cause both dysenteric (gross blood in diarrheal stools) and non-dysenteric clinical forms of moderate-to-severe diarrhea. Whereas dysentery is an indication for treatment with anti-Shigella antibiotics, non-dysenteric diarrhea is not typically treated with antibiotics. Thus, it was of particular interest to observe that Shigella not only significantly increased the risk of death in children with non-dysenteric moderate-to-severe diarrhea, but it was also quite common when detected by highly sensitive molecular diagnostic techniques.

Kathleen Neuzil, MD, MPH, FIDSA鈥淐VD鈥檚 GEMS research provides important data showing the need to better prevent and treat diarrheal illness. Over the past decade we鈥檝e seen a decline in child mortality linked to diarrheal illness, but certainly more needs to be done,鈥� said Kathleen Neuzil, MD, MPH, the Myron M. Levine Professor in Vaccinology, Professor of BOB体育 and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD).

E. Albert Reece, MD, PhD, MBAThe research is designed to help set a path for better prevention and treatment of diarrheal illness in children. 鈥淭his research underscores our commitment to take on the most challenging illnesses for the world鈥檚 vulnerable populations,鈥� said Dean E. Albert Reece, MD, PhD, MBA. 鈥淥ur Global Enteric Multicenter Study research continues to serve as a key guide for policy makers as they move toward preventing child mortality and designing the best interventions for children suffering from diarrheal illness,鈥� added Dean Reece, who is also Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor, University of Maryland School of BOB体育.

About the University of Maryland School of BOB体育

Now in its third century, the University of Maryland School of BOB体育 was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 45 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of BOB体育 and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1.2 billion, the School of BOB体育 works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of BOB体育 has more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of BOB体育 has a total population of nearly 9,000 faculty and staff, including 2,500 student trainees, residents, and fellows. The combined School of BOB体育 and Medical System (鈥淯niversity of Maryland BOB体育鈥�) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of BOB体育 faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School of BOB体育 works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

About the UMSOM Center for Vaccine Development and Global Health

For over 40 years, researchers in the Center for Vaccine Development and Global Health have worked domestically and internationally to develop, test, and deploy vaccines to aid the world鈥檚 underserved populations. CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has worked to eliminate vaccine-preventable diseases. CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal Salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, malaria and other infectious diseases. CVD鈥檚 research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. CVD researchers are developing new and improved ways to diagnose, prevent, treat, control, and eliminate diseases of global impact. Currently, these diseases include typhoid, Shigella, E. coli diarrhea, malaria, and other vaccine-preventable infectious diseases. CVD researchers have been involved in critical vaccine development for emerging pathogens such as Ebola and Zika. In addition, CVD鈥檚 work focuses on the ever-growing challenge of anti-microbial resistance.

About the Bill and Melinda Gates Foundation

Guided by the belief that every life has equal value, the  works to help all people lead healthy, productive lives. In developing countries, the foundation focuses on improving people鈥檚 health and giving them a chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people鈥攅specially those with the fewest resources鈥攈ave access to the opportunities they need to success in school and life. Based in Seattle, Washington, the foundation is led by CEO Sue Desmond-Hellmann and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.

Contact

Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Joanne Morrison
Director of Marketing and Public Relations
University of Maryland School of BOB体育
[email protected]
Office: (410) 706-2884
Mobile: (202) 841-3369

Related stories

    Thursday, December 16, 2021

    Novavax COVID-19 Vaccine Found to be Safe and Effective in Phase 3 Trial Conducted by UM School of BOB体育 Researchers

    An investigational COVID-19 vaccine made by Novavax was found to be 90 percent effective at preventing COVID-19 illness, according to results from a Phase 3 clinical trial published today in the New England Journal of BOB体育. The University of Maryland School of BOB体育’s (UMSOM) Center for Vaccine Development and Global Health served as one of the trial sites, and Karen Kotloff, MD, Professor of Pediatrics at UMSOM, served as Co-Chair for the trial protocol.


    Wednesday, October 30, 2019

    UM School of BOB体育's Myron M. Levine, MD, DTPH, to Receive Prestigious Lifetime Award for Five Decades of Pioneering Vaccine Research

    Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor at the University of Maryland School of BOB体育 (UMSOM), Associate Dean for Global Health, Vaccinology and Infectious Diseases, and Founder and Former Director of the Center for Vaccine Development and Global Health (CVD) is a co-recipient of the 2020 Research! America Geoffrey Beene Foundation Builders of Science Award for his pioneering vaccine and infectious disease research.


    Monday, May 06, 2019

    UM School of BOB体育's Dr. Karen Kotloff Receives 2019 Alumni Achievement Award from Temple University

    Karen Kotloff, MD, Professor of Pediatrics at the University of Maryland School of BOB体育 (UMSOM), has received the 2019 Alumni Achievement Award from the Lewis Katz School of BOB体育 at Temple University.


    Thursday, December 20, 2018

    Data From Largest Global Diarrheal Disease Study Available to Scientists on Public Sites

    Data collected from the Global Enteric Multicenter Study (GEMS), a multi-site research project studying diarrheal diseases that was designed and coordinated by researchers in the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of BOB体育 (UMSOM), are now available to scientists on two online data resources.


    Monday, October 15, 2018

    University of Maryland School of BOB体育 Scientists Receive Prestigious UMB Founders Week Awards

    Several experts at the UMSOM received prestigious awards commemorating the UMB 2018 Founders Week. Among them, Karen Kotloff, MD, Professor of Pediatrics, was named "Researcher of the Year" for her extensive work in infectious diseases in the U.S. and developing countries. The MARS team – Steven I. Hanish, MD, Visiting Associate Professor of Surgery, Thomas M. Scalea, MD, FACS, FCCM, The Honorable Francis X. Kelly Distinguished Professor in Trauma Surgery, and Deborah Stein, MD, MPH, FACS, FCCM, The R Adams Cowley, MD Professor in Shock and Trauma– were named "Entrepreneurs of the Year" for their liver dialysis device called the Molecular Absorbent Recirculating System (MARS).


    Monday, September 11, 2017

    Research Identifies Causes and Possible Treatments for Deadly Diseases Affecting Children in Developing Countries

    University of Maryland School of BOB体育 Researchers Explore How to Prevent Diarrheal Diseases, a Leading Cause of Death in Young Children in Sub-Saharan Africa and South Asia


    Thursday, June 08, 2017

    University of Maryland School of BOB体育 Vaccine Researcher Receives Top Award in the Study of Infectious Diseases from National Foundation

    Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Disease at UM SOM, has been awarded the Maxwell Finland Award for Scientific Achievement by the National Foundation for Infectious Diseases (NFID).


    Monday, May 15, 2017

    UM SOM Vaccine Researcher Receives Top Award in the Study of Infectious Diseases

    Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Disease at UM SOM, has been awarded the Maxwell Finland Award for Scientific Achievement by the National Foundation for Infectious Diseases (NFID). The award honors his extensive accomplishments in public health; over his career, he has identified solutions to major sources of disease in the developing world, including cholera, typhoid, and Shigella dysentery. The award will be presented on Thursday, May 18, 2017 at the Hyatt Regency Bethesda in Bethesda, Md.


    Friday, December 23, 2016

    Trial Results Confirm Ebola Vaccine Provides High Protection Against Disease

    An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to a new study that included researchers from the University of Maryland School of BOB体育 (UM SOM).


    Wednesday, June 29, 2016

    UM SOM Researchers Awarded Grant to Use Innovative Alternative to Autopsies to Better Understand Child Mortality

    Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development (CVD) at the University of Maryland School of BOB体育 (UM SOM), and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that CVD has been awarded a large grant from the Bill & Melinda Gates Foundation for research that will help determine why so many children under five are dying in the world’s poorest countries. The grant will fund use of an innovative alternative to traditional autopsy known as minimally invasive tissue sampling. The technique, which involves the collection of tissue samples with fine needles, allows researchers to quickly identify the cause of death, and help illuminate ways to save lives and improve the health of children in these vulnerable areas.


    Friday, June 10, 2016

    FDA Approves Vaccine for Cholera Invented and Developed at University of Maryland School of BOB体育

    In a milestone that was years in the making, a vaccine to prevent cholera, invented and developed by researchers at the University of Maryland School of BOB体育’s Center for Vaccine Development, was approved today by the U.S. Food and Drug Administration (FDA).